Molecular Targeted Therapies Provide Ray Of Hope For The Future Says New Informa Healthcare Book

Main Category: Cancer / Oncology
Also Included In: Immune System / Vaccines
Article Date: 07 Apr 2008 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

informa Healthcare, one of the premier medical scientific publishers in the United States, will publish this week a complete bench-to- bedside guide to cancer vaccines in development.

Advances in translational research have made it possible for clinical researchers to customize cancer treatments to match a patient's specific needs. More recent developments have pushed customization of investigational treatment fast forward so that clinicians can today, using a theranostic approach, match a patient's DNA and molecular structures.

Cancer Vaccines: Challenges and Opportunities in Translation-informa Healthcare's latest addition to its successful Translational Medicine series-traces gaps, challenges, and difficulties encountered in the past, including hurdles associated with the translation of immunology research into clinical opportunities, while outlining potential solutions and strategies for success.

Cancer Vaccines: Challenges and Opportunities in Translation's perspective is unique in that it covers topics relevant to industry, translation and development - with an eye on science as well as improving patient care.

Autologous and 'off-the-shelf' approaches - such as cancer vaccines - promise to deliver faster recuperation periods and a decreased chance of re-occurrence of malignancies - both of which will forever alter the current standard of cancer care. As Drs. Bot and Obrocea, the book editors, state ".in this post-genomic era, it is time to translate this vast scientific information and expand the healthcare benefits by adding vaccines to the large arsenal of cancer therapy in the quest of continuing to improve on the treatment and quality of life of all cancer patients."

Cancer Vaccines: Challenges and Opportunities in Translation adapts all the latest scientific discoveries pertaining to the development and optimization process of cancer vaccines to clinical practice, making it an especially valuable resource for scientists, researchers, and clinicians worldwide.

This book is available from wholesalers, online retailers, book stores, as well as directly from informa Healthcare through www.crcpress.com.

Other titles in the series include:

Diabetes: Translating Research into Practice, 2008 Cancer Supportive Care: Advances in Therapeutic Strategies, 2008 Cancer Vaccines: Challenges and Opportunities in Translation, 2008 Melanoma: Translational Research and Emerging Therapies, 2008 Breast Cancer: Translational Therapeutic Strategies, 2007 Lung Cancer: Translational and Emerging Therapies, 2007 Multiple Myeloma: Translational and Emerging Therapies, 2007 Prostate Cancer: Translational and Emerging Therapies, 2006

About the Editors

Adrian Bot is the author of more than one hundred publications, abstracts and patents and the Editor-in-Chief of the International Reviews of Immunology. Dr. Bot is Senior Director of Scientific Management and Acting Head of Translational Medicine at MannKind Corporation in Valencia, California. In addition, Dr. Bot has previously held appointments at Scripps Research Institute and Alliance Pharmaceutical Corp. in San Diego, and is a past and present scientific advisory member of several industry-leading institutions. He has an M.D. from the University of Medicine and Pharmacy in Timisora, Romania, and a Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in New York.

Mihail Obrocea received his M.D. degree from University of Medicine and Pharmacy in Bucharest, Romania and completed a fellowship program in Hematology/Oncology at Dartmouth-Hitchcock Medical Center in New Hampshire. Dr. Obrocea is Vice President of Clinical Development, Oncology at MannKind Corporation in Paramus, New Jersey. In addition, Dr. Obrocea held appointments in oncology drug development at Pfizer and MedImmune. He is also a published author with over a decade of academic and pharmaceutical industry experience in the field of oncology clinical trials. In addition Dr. Obrocea holds several patents in the field of biotechnology.

About informa Healthcare

informa Healthcare is a new force in science publishing that delivers authoritative research and analysis, up-to-the-minute news, comment and debate for all sectors of the Healthcare and Life Sciences communities. informa Healthcare serves the commercial needs of business leaders, the research needs of the scientific community and the 'good practice' needs of healthcare professionals around the world. The company, headquartered in London, England, is a division of Informa plc (London: INF) which employs 7,500 staff worldwide, and has offices in six continents.

informa Healthcare